FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783105483> ?p ?o ?g. }

• W2783105483 endingPage "6" @default.
• W2783105483 startingPage "3" @default.
• W2783105483 abstract "The wide world of medicinal chemistry: We look back at our activities in 2017, particularly the expansion of the journal′s scope to nanomedicine and why we need a more inclusive medicinal chemistry journal. Additionally, we look at upcoming special issues and developments for ChemPubSoc Europe in 2018. Although the roots of medicinal chemistry lie in synthetic organic chemistry, the field as it stands today is richer and wider than ever. Gone are the days when a medicinal chemistry journal or conference was limited to reports of synthesis, followed by some structure–activity relationship investigation, and then a demonstration of biological activity. In the past decade, we′ve seen studies with more depth, more structural knowledge, and more mechanistic insight. Computational methods have also become crucial to efficient and smarter drug discovery, with useful cheminformatic tools being developed continuously. What encompasses medicinal chemistry now includes therapeutics involving novel materials and methods, notably in the nanoscale. Additionally, chemical biology′s importance in drug discovery is at the forefront, including bioorthogonal methods, proteomic and metabolomic methods, and other biochemistry-centric techniques to complement both phenotypic and target-based drug discovery. Although small-molecule therapeutics remain the bedrock of medicinal chemistry, the rise of biopharmaceuticals or biologics (typically biomacromolecular therapeutics, protein therapy, antibody/antibody–drug conjugates, nucleic acid therapy, and immunotherapy) is also not to be ignored. Attend a medchem conference these days, and special sessions on chemical biology, biophysics, materials, biologics, and cheminformatics for drug discovery are a usual sight. A professor at a recent medicinal chemistry congress even mentioned, “If you want to have a good presentation here, you′ll have to please the organic chemists, the computational chemists, the biochemists, the biologists, and the pharmacologists all at once.” Interdisciplinarity is the name of the game these days, and more medicinal chemists are truly taking this to heart. It was in the spirit of a growing, more inclusive medicinal chemistry community that ChemMedChem decided to formally expand its scope to include nanomedicine in 2017. We added more board members in this field, solicited articles from specialists, and opened up nanomed transfers from sister journals like Angewandte Chemie, Chemistry—A European Journal, ChemNanoMat, and also from the Wiley-VCH Advanced materials portfolio. As a result, we were able to publish more nanomedicine articles in 2017 than ever before. Some outstanding papers even made it to the cover of the journal (Figure 1). Our 2017 covers featuring nanomedicine articles. From left to right: Issue 1, Utility of the 2-Nitrobenzenesulfonamide Group as a Chemical Linker for Enhanced Extracellular Stability and Cytosolic Cleavage in siRNA-Conjugated Polymer Systems (Takemoto, Nishiyama et al. ); Issue 12, Lanthanide Complexes in Molecular Magnetic Resonance Imaging and Theranostics (Tóth and Lacerda); Issue 19, Regulated Drug Release Abilities of Calcium Carbonate–Gelatin Hybrid Nanocarriers Fabricated via a Self-Organizational Process (Murai et al.); Issue 21, Fine and Clean Photothermally Controlled NIR Drug Delivery from Biocompatible Nickel-bis(dithiolene)-Containing Liposomes (Camerel et al.). All recent nanomedicine articles are free to access until March 2018 at bit.ly/cmdcnanomed. The success from expanding our scope and promoting this heavily in the past year was also reflected by the number of submitted manuscripts, which increased by more than 25% in 2017. Although our top five contributors (China, India, Italy, USA, Germany) have not changed in the past six years, the rise of China and India as top contributors is notable. (Figure 2). With the broadened scope, we only expect contributions from Asia to rise in the coming years, especially given the quick growth of nanomed research in this region. Article submission has almost tripled in the past decade (total number of papers reflected by the column width). The top contributors have also shifted from Italy and Germany (which could be thought of as “parent countries” of the journal) in 2007 to China and India in 2017. This increased manuscript flow coming from non-European countries is welcome, as this truly reflects the journal′s identity of being owned by European societies, but aimed at the global community. In the end, we not only want to be more expansive in terms of scope, but also in terms of the authorship and readership of the journal. In line with this, in the coming years, we also aim to reach out to more local medicinal chemistry societies/communities, and also actively look for referees, authors, and guest editors from regions that haven′t had as much interaction with the journal before. Finally, a word about publishing times. In 2017, all authors had the option to publish their accepted work quickly as “Accepted Articles”. These are the unedited versions of accepted manuscripts which go online within an hour of upload. These are eventually replaced after copyediting, typesetting, and proof correction (the so-called “version of record”). The majority of our authors have opted to publish their work in this form, leading to an average publication time of just five to six weeks, from submission to online article. ChemMedChem is part of a bigger ChemPubSoc Europe family, and 2018 brings new features for all the sister journals. The app is available for (iOS) and (Android). We will soon cut off content feeds to the individual journal apps, so get the new family app now and enjoy the added features! In the fall of 2016, Wiley acquired Atypon, a leading software development company for online publishing. In early 2018, Wiley Online Library will be upgraded to Atypon technology. We're looking forward to the new look and feel of the site, as well as exciting development opportunities. Lastly, as in 2017, we encourage our readers to carefully consider transfer options to ChemMedChem or any of our sister journals. Sometimes, because of a journal′s stringent selection process, a manuscript narrowly misses out on publication. As most of these papers still report good science, the handling editor can offer a transfer to a sister journal, where the manuscript can get another chance at being published. For ChemPubSoc Europe journals, we highly recommend that authors consider these transfer offers for a couple of reasons: 1) It expedites the peer review process in the new journal, and in some cases could lead previously reviewed papers that have been throroughly revised to be immediately accepted by the receiving journal. 2) It saves you time as you do not have to input the submission information a second time. To learn more about why you should agree to an article transfer, check out the article by Editors Anne Deveson and Theresa Kueckmann on ChemistryViews (bit.ly/whytransfer) This year, we have a number of exciting Special Issues lined up. In the first quarter, we have cheminformatics in drug discovery, guest edited by Dr. Nathan Brown (BenevolentAI; ChemMedChem Advisory Board) and Dr. Andreas Bender (University of Cambridge). Although the journal has published a few purely computational papers in the past, this is the first time we have collected articles on this topic featuring leaders in the field. Midyear, we expect to publish two Special Issues on nanomedicine. The first will focus on theranostics and will be guest edited by Prof. Eva Tóth (French National Centre for Scientific Research) and Prof. Zhuang Liu (Soochow University), both on the ChemMedChem Advisory Board. The second will focus on nanodrugs and drug delivery, and will be guest edited by Prof. Sangyong Jon (Korea Advanced Institute of Science and Technology, ChemMedChem Advisory Board) and Prof. Yiyun Cheng (East China Normal University). Towards the end of 2018, we look forward to the Special Issue on neglected tropical diseases, guest edited by Prof. Kelly Chibale (University of Cape Town) and Prof. Paul Wyatt (University of Dundee, ChemMedChem Advisory Board), and that on novel antibacterials, guest edited by Prof. Rolf W. Hartmann (Helmholtz Institute for Pharmaceutical Research Saarland, ChemMedChem Advisory Board) and Prof. Bill Wuest (Emory University). To supplement the Special Issues and bring some hot topics to the forefront, we will be launching regular Virtual Issues throughout the year. A list of available Virtual Issues will be available on our homepage. First up is the Virtual Issue on nanomedicine, as a prelude to the Special Issues later this year. This is available at bit.ly/cmdcnanomed now and is free to read until March 2018! Last year, we supported and attended quite a few conferences all over the world. The largest of which was the 11th Asian International Medicinal Chemistry Symposium (AIMECS), held under the Centenary Royal Australian Chemical Institute (RACI) Congress in Melbourne (July 2017). The mega-congress ran over six days at the Melbourne Convention and Exhibition Centre, with over 3000 chemists attending. Editors from Wiley-VCH attended to promote the journals, meet our board members, and discuss the work of valued authors and reviewers from the region (Figure 3). ChemMedChem sponsored some poster prizes and also launched a Virtual Issue on Medicinal Chemistry in Australia (bit.ly/cmdcRACI100). Our presence at the 2017 Asian International Medicinal Chemistry Symposium (AIMECS) under the Royal Australian Chemical Institute (RACI) Centenary Congress. a) A koala reaches out for a copy of Angewandte Chemie at the welcome reception sponsored by Wiley-VCH and ChemPubSoc Europe. b) Peter Gölitz (then Angewandte Chemie Editor) hands out free ice cream during the “Meet the Editors” session at the Wiley-VCH booth. c) AIMECS chair Prof. Renate Griffith with David Peralta (ChemMedChem Editor). d) ChemMedChem′s Australian board members, Prof. Michael Kassiou and Prof. Dave Winkler. e) Marketing manager Karina Partisch at the Wiley-VCH booth, giving out #Chemquackers ducks. This year, the journal is actively supporting three major conferences in Europe—1) The Frontiers in Medicinal Chemistry (FiMC) meeting by the German Chemical Society (GDCh) in Jena, March 11–14; 2) The Italian–Spanish–Portuguese Joint Meeting in Medicinal Chemistry (MedChemSicily2018) in Palermo, July 17–20; and 3) The XXV International Symposium on Medicinal Chemistry by the European Federation for Medicinal Chemistry (EFMC-ISMC) in Ljubljana, September 2–6. Additional conferences are in the pipeline, and details on these will be available from the journal′s website and Twitter feed throughout the year. In 2018, we invite our readers and authors again to contribute more Review-type articles in their areas of research. This year especially, we are interested in publishing Patent Reviews. Patent Reviews offer a summary and discussion of selected patents that fall within the scope of the journal. The patents discussed can be related by a similar compound class, a similar target pathway/disease, or similar mechanisms of action. Similar to regular Review articles, rather than a simple collection of detailed information with a complete literature survey, a critical treatment of the material is desired. Authors are expected to be objective in their selection and evaluation of the patents, and must not focus solely on their own research. Discussions of single patents are not permitted, and all patents discussed must be relatively new (granted only within the past 1–4 years). Patent Reviews should contain a brief Abstract, which should provide the background of the compound class or targeted disease/mechanism and give the reader an indication of these related patents are worthy of highlight. ChemMedChem Patent Reviews begin with an Introduction which gives the background of the compound class and the targeted disease/pathway. The Patent Discussion section then follows with the crucial information on the patents. Here, authors are expected to discuss the relevance/significance of the patents within the broader field of drug development or the disease in question. The patent history and any updates are mentioned here as well, especially for key compounds that have reached clinical trials (whether they succeeded or not). Authors should provide their own critique and commentary on the patents and not just have a simple listing. The final section is the Outlook, where authors share their own thoughts on future directions regarding these patents/compounds. As an incentive, Patent Reviews published within 2018 will be set as free-to-read for the rest of the year. Authors who wish to write a Review-type article should propose their topic and the planned scope/outline to the Editorial Office before writing a manuscript. As a final word, I would like to thank everyone who has helped ChemMedChem in 2017. With our unprecedented submission rate, board and scope expansion, and participation in medicinal chemistry events throughout the year, 2017 has indeed been a success, and with your help, I look forward to further strengthening the journal in 2018. Dr. David Peralta David Peralta was named Editor-in-Chief of ChemMedChem as of July 1, 2017. The appointment was confirmed by society representatives at the annual meeting of ChemPubSoc Europe and Wiley-VCH in Berlin last September. Dr. Peralta earned his B.S. in chemistry at the Ateneo de Manila University, Philippines, in 2006. He finished his master′s degree there as well, focusing on bio-, organic, and analytical chemistry, specifically working on carbohydrate-active enzymes. While finishing his M.S. degree, he also taught undergraduate classes in general chemistry, biochemistry, and science & society. On the side, he finished an additional degree in German studies, which eventually inspired him to pursue his Ph.D. in Germany. In 2009, he moved to Heidelberg for his Ph.D. at the German Cancer Research Center (DKFZ), in the research group of Prof. Tobias Dick (Division of Redox Regulation), where he focused on redox biochemistry and uncovered a mechanism for the H2O2-sensitivity of the moonlighting enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In 2015, he earned his Ph.D. in biosciences, summa cum laude, from the DKFZ and the Ruprecht-Karls-Universität Heidelberg. Shortly before his doctoral defense, he joined Wiley-VCH in 2014 as an Assistant Editor for both ChemMedChem and ChemistryOpen, and later also ChemistrySelect. In 2016, he became Managing Editor of ChemMedChem. More information can be found in the ChemistryViews interview at (bit.ly/cmdceditor2017)" @default.
• W2783105483 created "2018-01-26" @default.
• W2783105483 creator A5071918384 @default.
• W2783105483 date "2018-01-08" @default.
• W2783105483 modified "2023-10-18" @default.
• W2783105483 title "Diversity in Medicinal Chemistry" @default.
• W2783105483 doi "https://doi.org/10.1002/cmdc.201700803" @default.
• W2783105483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29314769" @default.
• W2783105483 hasPublicationYear "2018" @default.
• W2783105483 type Work @default.
• W2783105483 sameAs 2783105483 @default.
• W2783105483 citedByCount "1" @default.
• W2783105483 countsByYear W27831054832022 @default.
• W2783105483 crossrefType "journal-article" @default.
• W2783105483 hasAuthorship W2783105483A5071918384 @default.
• W2783105483 hasBestOaLocation W27831054831 @default.
• W2783105483 hasConcept C144024400 @default.
• W2783105483 hasConcept C185592680 @default.
• W2783105483 hasConcept C19165224 @default.
• W2783105483 hasConcept C2781316041 @default.
• W2783105483 hasConceptScore W2783105483C144024400 @default.
• W2783105483 hasConceptScore W2783105483C185592680 @default.
• W2783105483 hasConceptScore W2783105483C19165224 @default.
• W2783105483 hasConceptScore W2783105483C2781316041 @default.
• W2783105483 hasIssue "1" @default.
• W2783105483 hasLocation W27831054831 @default.
• W2783105483 hasLocation W27831054832 @default.
• W2783105483 hasOpenAccess W2783105483 @default.
• W2783105483 hasPrimaryLocation W27831054831 @default.
• W2783105483 hasRelatedWork W1531601525 @default.
• W2783105483 hasRelatedWork W1990781990 @default.
• W2783105483 hasRelatedWork W2033045522 @default.
• W2783105483 hasRelatedWork W2314643286 @default.
• W2783105483 hasRelatedWork W2344122601 @default.
• W2783105483 hasRelatedWork W2607424097 @default.
• W2783105483 hasRelatedWork W2748952813 @default.
• W2783105483 hasRelatedWork W2899084033 @default.
• W2783105483 hasRelatedWork W2948807893 @default.
• W2783105483 hasRelatedWork W2778153218 @default.
• W2783105483 hasVolume "13" @default.
• W2783105483 isParatext "false" @default.
• W2783105483 isRetracted "false" @default.
• W2783105483 magId "2783105483" @default.
• W2783105483 workType "article" @default.